Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
08:17am, Tuesday, 04'th May 2021
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stoc
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
06:30am, Tuesday, 04'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peopl
Sage Therapeutics to Present at Upcoming May Investor Conferences
06:30am, Wednesday, 28'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
06:30am, Tuesday, 20'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
11:45am, Monday, 12'th Apr 2021
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
10:36am, Wednesday, 07'th Apr 2021
Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.
Knocked Down, These 3 Stocks May Rise Again
10:06am, Monday, 05'th Apr 2021
When stocks are punished, it's not always for a good reason.
Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day
06:30am, Wednesday, 24'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass
06:11am, Sunday, 21'st Mar 2021
Can this brain health-focused biotech continue to rise, or will it fade -- again?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open
Sage Therapeutics Announces Departure of Chief Operating Officer
04:45pm, Tuesday, 16'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili
AT&T, Expedia, Mattel, Urban Outfitters and More Thursday Afternoon Analyst Calls
12:17pm, Thursday, 25'th Feb 2021
With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q4 2020 Results - Earnings Call Transcript
02:23pm, Wednesday, 24'th Feb 2021
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q4 2020 Results - Earnings Call Transcript
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
06:30am, Wednesday, 24'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform th
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:40pm, Wednesday, 17'th Feb 2021
Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
